Public Market Listing
688266 SSE STAR Market
SSE STAR Market primary exchange listing
External market data link · No third-party exchange redistribution
Assets (2 total) 2 Total Assets
0 Approved
2 Phase 3 / Filed
0 Phase 1–2 / Early
5 Diseases
Disease: All diseases (2) Atopic Dermatitis (1) Myelofibrosis (1) Alopecia Areata (1) Non-Small Cell Lung Cancer (1) Hepatocellular Carcinoma (1)
Stage: All stages (2) Approved / Phase 4 (0) Phase 3 / Filed (2) Phase 2 Phase 1 / Preclinical
Quick filter: All (2) Atopic Dermatitis (1) Myelofibrosis (1) Alopecia Areata (1) Non-Small Cell Lung Cancer (1) Hepatocellular Carcinoma (1)
Showing 2 of 2 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 JAK1/2/3 Small molecule
Atopic Dermatitis Myelofibrosis Alopecia Areata
Phase 3 PD-1 and TIGIT Biologic (subtype unspecified)
Non-Small Cell Lung Cancer Hepatocellular Carcinoma
Upcoming events (10 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2027 (8) April 2027 (2) Est. primary completion 2027-04 ·
NCT06883526 ·
CT.gov ↗ What to watch
May 2027 (2) Nilvanstomig Phase 1/2 Advanced Solid Tumor Est. primary completion 2027-05 ·
NCT06938880 ·
CT.gov ↗ What to watch
Nilvanstomig Phase 2 Advanced Solid Tumor Est. primary completion 2027-05 ·
NCT06927687 ·
CT.gov ↗ What to watch
August 2027 (1) Est. primary completion 2027-08 ·
NCT07080216 ·
CT.gov ↗ What to watch
September 2027 (1) Nilvanstomig Phase 1/2 Small Cell Lung Cancer, Neuroendocrine Carcinoma Est. primary completion 2027-09 ·
NCT07038096 ·
CT.gov ↗ What to watch
October 2027 (1) December 2027 (1) Nilvanstomig Phase 2 Biliary Tract Carcinoma Est. primary completion 2027-12 ·
NCT07099547 ·
CT.gov ↗ What to watch
2031 (2) September 2031 (1) Nilvanstomig Phase 3 Hepatocellular Carcinoma Est. primary completion 2031-09 ·
NCT07813572 ·
CT.gov ↗ What to watch
October 2031 (1) Nilvanstomig Phase 3 Neuroendocrine Carcinomas (NEC) Est. primary completion 2031-10 ·
NCT07833839 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (3) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
13 April 2026 Topline result jaktinib ZGJAK025 (NCT05526222) Phase 3 in moderate-to-severe atopic dermatitis met its primary endpoints Suzhou Zelgen Biopharmaceuticals Co., Ltd. ·
Source ↗ 21 October 2025 Topline result jaktinib ZGJAK029 (NCT05861102) Phase 3 in active ankylosing spondylitis met its primary endpoint 苏州泽璟生物制药股份有限公司 (Suzhou Zelgen Biopharmaceuticals Co., Ltd.) ·
Source ↗ 13 June 2024 Topline result jaktinib ZGJAK018 (NCT05051761) Phase 3 in severe alopecia areata met its primary endpoint 苏州泽璟生物制药股份有限公司 (Suzhou Zelgen Biopharmaceuticals Co., Ltd.) ·
Source ↗ Financial reports Annual history (2 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $113M $60M $18M — report ↗
View 1 more year Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $74M $54M $30M — report ↗